ABO-incompatible kidney transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 4, 2012, Pages 376-385

  Fehr, Thomas ^a   Stussi, Georg ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

ABO incompatibility; immunoadsorption; kidney transplantation; plasmapheresis; rituximab

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; BASILIXIMAB; BLOOD GROUP ANTIBODY; BLOOD GROUP ANTIGEN; BORTEZOMIB; CORTICOSTEROID; CYCLOSPORIN; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; VALACICLOVIR; VALGANCICLOVIR;

BLOOD GROUP ABO INCOMPATIBILITY; CHIMERA; CHRONIC GRAFT REJECTION; COMPLEMENT DEPENDENT CYTOTOXICITY; DESENSITIZATION; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT RECIPIENT; GRAFT SURVIVAL; HERPES VIRUS INFECTION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOADSORPTION; IMMUNOGENICITY; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PLASMAPHERESIS; REVIEW; SPLENECTOMY; T LYMPHOCYTE; UPREGULATION;

ABO BLOOD-GROUP SYSTEM; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 84864700188     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328355f013     Document Type: Review

References (62)

1. Paul LC, van Es LA, Riviere GB, et al. Blood group B antigen on renal endothelium as the target for rejection in an ABO-incompatible recipient. Transplantation 1978; 26:268-271.
2. Raja R, Bannett A, Caruana R, et al. Removal of antibodies with immunoadsorption from an ABO incompatible recipient prior to renal transplant. ASAIO Trans 1986; 32:102-103.
3. Agishi T, Takahashi K, Yagisawa T, et al. Immunoadsorption of anti-A or anti-B antibody for successful kidney transplantation between ABO incompatible pairs and its limitation. Japanese Biosynsorb Research Group. ASAIO Trans 1991; 37:M496-M498.
4. Roodnat JI, Kal-van Gestel JA, Zuidema W, et al. Successful expansion of the living donor pool by alternative living donation programs. Am J Transplant 2009; 9:2150-2156.
5. Rees MA, Kopke JE, Pelletier RP, et al. A nonsimultaneous, extended, altruistic-donor chain. N Engl J Med 2009; 360:1096-1101.
6. Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant 2010; 10:449-457.
7. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995; 13:655-692.
8. Rose ML, West LJ. Accommodation: does it apply to human leukocyte antigens? Transplantation 2012; 93:244-246.
9. Stussi G, Huggel K, Lutz HU, et al. Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method. Br J Haematol 2005; 130:954-963.
10. Tyden G, Donauer J, Wadstrom J, et al. Implementation of a Protocol for ABOincompatible kidney transplantation: a three-center experience with 60 consecutive transplantations. Transplantation 2007; 83:1153-1155.
11. Shirey RS, Cai W, Montgomery RA, et al. Streamlining ABO antibody titrations for monitoring ABO-incompatible kidney transplants. Transfusion 2010; 50:631-634.
12. Yung GP, Valli PV, Starke A, et al. Flow cytometric measurement of ABO antibodies in ABO-incompatible living donor kidney transplantation. Transplantation 2007; 84:S20-S23.
13. WahrmannM, Schiemann M, Marinova L, et al. Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. Nephrol Dial Transplant 2012; 27:2122-2129.
14. Etheredge EE, Bettonville P, Sicard GA, et al. Antierythrocyte antibodies, leukocytotoxins and human renal allograft survival. Tissue Antigens 1982;19:205-212.
15. Higgins R, Lowe D, Hathaway M, et al. Double filtration plasmapheresis in antibody-incompatible kidney transplantation. Ther Apher Dial 2010; 14:392-399.
16. Genberg H, Kumlien G, Wennberg L, et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85:1745-1754.
17. Valli PV, Puga YG, Fehr T, et al. Changes of circulating antibody levels induced by ABO antibody adsorption for ABO-incompatible kidney transplantation. Am J Transplant 2009; 9:1072-1080.
18. Genberg H, Kumlien G, Wennberg L, et al. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABOincompatible kidney transplantation. Nephrol Dial Transplant 2011; 26: 2394-2400.
19. Teschner S, Stippel D, Grunenberg R, et al. ABO-incompatible kidney transplantation using regenerative selective immunoglobulin adsorption. J Clin Apher 2012; 27:51-60.
20. Morath C, Becker LE, Leo A, et al. ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation 2012; 93:827-834.
21. Lawrence C, Galliford JW, Willicombe MK, et al. Antibody removal before ABO-incompatible renal transplantation: how much plasma exchange is therapeutic? Transplantation 2011; 92:1129-1133.
22. Ishida H, Koyama I, Sawada T, et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000; 70:681-685.
23. Tanabe K, Ishida H, Shimizu T, et al. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated nonsplenectomy preconditioning regimens. Contrib Nephrol 2009; 162:61-74.
24. Genberg H, Hansson A, Wernerson A, et al. Pharmacodynamics of rituximab in kidney transplantation. Transplantation 2007; 84:S33-S36.
25. Shirakawa H, Ishida H, Shimizu T, et al. The low dose of rituximab in ABOincompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant 2011; 25:878-884.
26. Ferraro AJ, Drayson MT, Savage CO, et al. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol 2008; 38:292-298.
27. Diwan TS, Raghavaiah S, Burns JM, et al. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 2011; 91:536-541.
28. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86:1754-1761.
29. Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486-1492.
30. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole postrenal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10:681-686.
31. Wahrmann M, Haidinger M, Kormoczi GF, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89:1385-1390.
32. Ishida H, Miyamoto N, Shirakawa H, et al. Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation: single center analysis. Am J Transplant 2007; 7:825-831.
33. Toki D, Ishida H, Horita S, et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009; 22: 447-454.
34. Wilpert J, Geyer M, Pisarski P, et al. On-demand strategy as an alternative to conventionally scheduled posttransplant immunoadsorptions after ABOincompatible kidney transplantation. Nephrol Dial Transplant 2007; 22: 3048-3051.
35. Takahashi K, Saito K, Takahara S, et al. Excellent long-term outcome of ABOincompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4:1089-1096.
36. Montgomery JR, Berger JC, Warren DS, et al. Outcomes of ABOincompatible kidney transplantation in the United States. Transplantation 2012; 93:603-609.
37. Shishido S, Hyodo YY, Aoki Y, et al. Outcomes of pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls. Transplant Proc 2012; 44:214-216.
38. Tyden G, Kumlien G, Berg UB. ABO-incompatible kidney transplantation in children. Pediatr Transplant 2011; 15:502-504.
39. Setoguchi K, Ishida H, Shimmura H, et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am J Transplant 2008; 8:86-94.
40. Oettl T, Halter J, Bachmann A, et al. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies. Nephrol Dial Transplant 2009; 24:298-303.
41. Oettl T, Zuliani E, Gaspert A, et al. Late steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation: high rate of mild cellular rejection. Transplantation 2010; 89:702-706.
42. Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12:469-476.
43. Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int 2012; 81:628-639.
44. Haas M, Segev DL, Racusen LC, et al. C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts. J Am Soc Nephrol 2009; 20:197-204.
45. Iwasaki K, Miwa Y, Ogawa H, et al. Comparative study on signal transduction in endothelial cells after anti-A/B and human leukocyte antigen antibody reaction: implication of accommodation. Transplantation 2012; 93:390-397.
46. Chen SS, Zhong S, Xiang Y, et al. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant 2011; 11:2057-2066.
47. Tanabe T, Ishida H, Horita S, et al. Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation. Transpl Immunol 2011; 25:1-6.
48. Varga Z, Gaspert A, Behnke S, et al. Tubular and endothelial chimerism in renal allografts using fluorescence and chromogenic in situ hybridization (FISH, CISH) technology. Pathol Int 2012; 62:254-263.
49. Kahwaji J, Sinha A, Toyoda M, et al. Infectious complications in kidneytransplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6:2894-2900.
50. Habicht A, Broker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients: a single centre experience. Nephrol Dial Transplant 2011; 26:4124-4131.
51. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10:89-98.
52. Yamamoto T, Kawaguchi T, Watarai Y, et al. Potent immunosuppression for ABO-incompatible renal transplantation may not be a risk factor for malignancy. Transplant Proc 2012; 44:210-213.
53. Segev DL, Simpkins CE, Warren DS, et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 5:2570-2575.
54. Montgomery RA, Locke JE. ABO-incompatible transplantation: less may be more. Transplantation 2007; 84:S8-S9.
55. Tobian AA, Shirey RS, King KE. ABO antibody titer monitoring for incompatible renal transplantation. Transfusion 2011; 51:454-457.
56. Fuchinoue S, Ishii Y, Sawada T, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011; 91:853-857.
57. Wilpert J, Fischer KG, Pisarski P, et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant 2010; 25:3778-3786.
58. Kato Y, Tojimbara T, Iwadoh K, et al. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Int Immunopharmacol 2006; 6:1984-1992.
59. Galliford J, Charif R, Chan KK, et al. ABO incompatible living renal transplantation with a steroid sparing protocol. Transplantation 2008; 86:901-906.
60. Gloor J, Matas AJ. Steroid-free maintenance immunosuppression and ABOincompatible transplantation. Transplantation 2010; 89:648-649.
61. Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87:1246-1255.
62. Flint SM, Walker RG, Hogan C, et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant 2011; 11:1016-1024.